34 results about "Anaerobic infection" patented technology

This invention provides wound healing systems, which delivers oxygen to the wound bed and applies negative pressure thereto, where the source of oxygen and negative pressure are simultaneously applied to distal sites of the dressing. Methods of treating wounds and methods of treating or preventing anaerobic infection of wounds using such systems are described.

The invention discloses metronidazole ophthalmic gel and a preparation method and an application thereof, which belong to the technical field of medicine. Metronidazole serving as a related medicinal active ingredient is prepared into ophthalmic gel for the first time. The metronidazole ophthalmic gel is applied to prevention and treatment of blepharitis ciliaris, hordeolum and conjunctivitis caused by worm acarus infection, and a dry eye syndrome caused by meibomian gland dysfunction, and is applied to prevention and treatment of infection of acanthamoeba protozoan and anaerobic bacteria in the wearing process of corneal contact lenses. The metronidazole ophthalmic gel consists of metronidazole and a pharmaceutically-acceptable vector, and the using amount of metronidazole in every 100g of the metronidazole ophthalmic gel is 0.1-3.0g by weight.

The invention relates to an amino-acid ester water-soluble derivative of (S)-ornidazole and application thereof. the amino-acid ester of (S)-ornidazole has a structure as shown in the formula (I), wherein R and (HnX)m are defined in the claims. The invention also relates to a preparation method of the compound as shown in the formula (I), pharmaceutical salt thereof, a pharmaceutical composition containing the compound and the pharmaceutical salt and application of the pharmaceutical composition used as a medicine, especially application of the pharmaceutical composition used for treatment of anaerobic infection or protozoan infection.

The present invention discloses freeze dried levo-ornidazole powder for injection as one anaerobic bacteria infection resisting medicine. The freeze dried levo-ornidazole powder for injection includes levo-ornidazole as main medicinal component and pharmaceutically acceptable carrier, includes solvent selected from one or several of ethanol, propylene glycol, glycerin, polyethylene glycol, Tween-80, etc. The freeze dried levo-ornidazole powder for injection may be prepared into specification containing levo-ornidazole of 1-2000 mg, preferably 0.25-1.5g and especially 0.25g, 0.5g and 1.0g. It has high stability, high curative effect and other features.

The invention relates to a stable pharmaceutical salt of L-aonitrate phosphate ester, its preparation method and application. The related strong acid salt of the L-aonitrate phosphate ester is shown by the formula I and is mainly used in treating anaerobic infection or protozoan infection.

The invention discloses application of a rifamycin-nitroimidazole coupling molecule represented in a formula I in inhibition of anaerobic or facultative anaerobic ammonia producing floras in gastrointestinal tracts. The rifamycin-nitroimidazole coupling molecule represented in the formula I is similar to an antibacterial spectrum of rifaximin and has relatively strong antibacterial activity to common ammonia producing floras in the gastrointestinal tracts; and meanwhile, the rifamycin-quinolizidone dual-target molecule has the property of low spontaneous drug resistance frequency and has very good application prospects in prevention and treatment of infection of hepatic encephalopathy and relevant anaerobic bacteria. The formula is as shown in the specification.

The invention relates to a nitroimidazole derivative used in therapy, and provides a compound of formula (I) or its pharmaceutical salt: wherein R1 can be taken as saturated or unsaturated straight chain, branched chain alkyl or cyclic alkyl with the carbon number from 1 to 10, R2, R3 can represent alkyl or form rings, the ring can be the ring from three-membered ring to ten-membered ring, the ring is capable of connecting with one or a plurality of same or different substituents; the rings formed by R2, R3 are capable of forming heterocycles, the heterocycle is capable of containing 0 to 5 same or different heteroatom substitutions; X expresses ion or group with negative electricity, which concretely can be halogen negative ion, organic acid radical, inorganic acid radical. According to the invention, the nitroimidazole derivative is used for treating the diseases caused by anaerobic infection or protozoans infection.

The invention provides toothpaste for a cat and belongs to the technical field of daily articles for animals. The toothpaste for the cat is prepared from the following raw materials of water, a lotus leaf extract, a hawthorn leaf extract, a catnip extract, glycerinum, salmon oil, taurine, panax notoginseng powder, xylitol, vitamin C, vitamin B2 and metronidazole. The invention further discloses a preparation method for the toothpaste for the cat. The catnip extract in the toothpaste disclosed by the invention appeals to the cat, so that the psychological conflict of the cat to the tooth cleaning is reduced; in addition, the toothpaste disclosed by the invention is free of alcohol and other components harmful to the cat; a flavone compound contained in the lotus leaf extract and the hawthorn leaf extract has better antibacterial effect on related pathogenic bacteria causing gingivitis, periodontitis, ozostomia and redness and swelling of the gum; besides, the breath of the cat can be kept fresh, and the gingiva problem of the cat is effectively solved, and dental calculus and dental plaque of an oral cavity of the cat can also be removed; oral infection is mostly caused by anaerobic infections, while the metronidazole has better inhibiting effect on the anaerobic infections, and does not easily generate drug resistance.

The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses.

The invention particularly relates to a drug for rapid-acting treatment of toothache. The drug integrates various causes of toothache disease and carries out the compounding of antibiotic anti-inflammatory drug, anti-spirit sensitivity drug, anti-anaerobic infection drug, anti-inflammatory analgesic drug and other various western patent drugs, and the compound drug mainly consists of drug cefalexin or other antibiotic anti-inflammatory drug, tiapride hydrochloride, metronidazole or other anti-anaerobic infection drug, indometacin enteric-coated tablet, phenylbutazone and prednisone hydrochloride sequentially according to the mixing ratio by weight parts. The drug of the invention is rapid in acting for the toothache disease which is formed by various causes, and generally the drug can act in 1 to 1.5 hours after the drug administration, the pain can be stopped after one week of the drug administration, and the effect is significant; the effective rate of the rapid pain stopping is 98 percent and the cure rate is 96.5 percent according to the statistics; the used drugs of the invention are the patent drugs which are proved by the state and the efficacies of the drugs are safe and reliable; the administration is convenient, which is easy to be accepted by patients.

The invention discloses a preparation of arteannuin for curing gynecological diseases illness and its producing method, which can effectively solve the problem caused by preparation. The invention discloses made by auxiliary materials, and its producing method is chattering and filtering arteannuin or its derivative separately, which are mixed averagely according to the requirement, then add inhibitory action or killing action made by alcohol and pathogen such as colpitis mycotica and trichomonad, make into particle, dry it, then spray organic acid made by citric acid onto the dried particles, add medical effect into the particle and focus. The invention has scientific and reasonable component, remarkable aromatic, convenient eliminating wetness-evil with drugs of fragrant flavor, advanced producing method.

The invention discloses a preparation method and application for tinidazole dispersing tablet. Said tinidazole dispersing tablet in the invention has merits of convenient for use, fast absorption, high biological utilization ratio, etc. also featuring simple technique , stable quality, convenient for carrying and storing. The amount of tinidazole contained in each tablet of Said tinidazole dispersing tablet in the invention can be 0.2g.,0.25g.,0.5g. The main clinical use for said medicine is applying to all sorts of infection from anaerobe, colon and rectum operation, operation for gynecology and obstetrics, etc.

The invention discloses a drug containing sustained-release ornidazole drug and used for treating infections of trichmonad, amoeba, giardia and anaerobic organism in gynecopathy as well as the preparation method thereof. The drug aims to provide a sustained-release ornidazole dropping pill formulation which has excellent curative effect, low toxic and side effects, broad-spectrum antibacterium, safer use, low frequency of drug taking and long effective hours and is prepared by adopting the solid dispersion technology, thereby thoroughly changing the defects existing in conventional oral formulations from the drug structure. The sustained-release ornidazole dropping pill adopts ornidazole as the ingredient and is prepared jointly with the medicinal carrier used as the stroma.

The invention discloses an applying and washing product containing kudzuvine root for eliminating inflammation, relieving itching, and caring and repairing skin. The product comprises wild firewood-shaped kudzuvine roots, herba houttuyniae, metronidazole, estradiol hemihydrate and camellia oil. The wild firewood-shaped kudzuvine roots contained in the product disclosed by the invention has a function of removing odor smells, the herba houttuyniae has a function of eliminating inflammation and promoting uresis, the metronidazole has a function of treating anaerobic infection, vaginal trichomonas infection and balantidoses infection; the estradiol hemihydrate has the effects of treating nutritional diseases, genitourinary tracts, vaginal atrophy of vulva, dyspareunia, incontinence of urine and mental illness as well as sleep disorder; and the camellia oil has functions of repairing and caring the skin. According to the product disclosed by the invention, as raw materials, the five ingredients act and regulate mutually, so that stimulation on female perineum is avoided while bacteria and odor smells are removed at the same time, invasion of pathogenic bacteria is reduced, and the product has the effects of repairing and caring the skin; and moreover, the product has good effects on senile vaginitis, pruritus, atrophy of vulva and dry sexual life pain.

The invention relates to the technical field of drugs, and relates to a preparation method of a two-component drug for treating tinea pedis. By virtue of oral administration and external application,the tinea pedis can be jointly healed; a component A is prepared, an extracted vitamin B family belongs to water soluble vitamins and has efficacies for regulating the metabolism, facilitating the regeneration of cells, keeping the health of the foot skin, preventing reoccurrence of the tinea pedis and improving the immunity system and the nervous system; the Chinese herb decoction has efficaciesfor clearing away the internal heat, eliminating the toxicity, repelling the wind, removing the dampness, nourishing the kidney, tonifying Qi, clearing and activating the channels and collaterals, promoting the foot bottom blood circulation, improving the immunity defense capacity of the body, promoting the healing of the tinea pedis, adjusting the immunity mechanism of the body, and controlling the reoccurrence and reducing the occurrence of the tinea pedis. The boric acid has an effect of inhibiting mycete, the salicylic acid can inhibit the fungus, soften the epidermis and remove cutin; methenamine has an effect of hidroschesis and convergence; the zinc oxide has an effect for relieving the itching and converging; phenol has a sterilizing and disinfecting effect; metronidazole can resist the anaerobic infection; nitrofurazone has an inflammation eliminating effect; and the two-component drug easily coats the skin surface to form a film, thereby playing the effect and promoting the healing of the tinea pedis.

The invention provides an oxazolidinone-nitroimidazole coupling molecule or application of a stereoisomer, hydrate, a deuterium substitute, ester, solvate, a crystal form, metabolite, pharmaceuticallyaccepted salt or prodrug of the coupling molecule in resisting anaerobic bacteria. The oxazolidinone-nitroimidazole coupling molecule is a compound as shown in formula I or II. The oxazolidinone-nitroimidazole coupling molecule or the stereisomer, hydrate, deuterium substitute, ester, solvate, crystal form, metabolite, pharmaceutically accepted salt or prodrug of the coupling molecule can be usedfor effectively resisting the anaerobic bacteria and then treating anaerobic bacteria-infected diseases.

The invention relates to tinidazole ophthalmic gel, and a preparation method and application thereof, and belongs to the technical field of medicines. Tinidazole serving as a medicinal active ingredient is prepared into ophthalmic gel for the first time, and the tinidazole ophthalmic gel is applied to the prevention and treatment of blepharitis ciliaris, hordeolum and conjunctivitis which are infected by worm mites, xerophthalmia caused by meibomian gland dysfunction and acanthamoeba protozoa in the process of wearing corneal contact lenses and anaerobic infection. The tinidazole ophthalmic gel consists of the tinidazole and a medicinally-acceptable carrier, and on the basis of the weight of the tinidazole ophthalmic gel, the using amount of the tinidazole is 0.1 to 3.0 grams in each 100 grams of tinidazole ophthalmic gel.

The invention provides an oxazolidone-nitroimidazole coupling molecule, or stereoisomers, hydrates, deuterated compounds, esters, solvates, crystal forms, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and application in anti-anaerobic bacteria, and belongs to the field of medicine. The oxazolidone-nitroimidazole coupling molecule has the structure shown in Formula I. The invention also provides application of the oxazolidone-nitroimidazole coupling molecule and a drug combination composition thereof in the preparation of drugs for the treatment of diseases caused by anaerobic infections. The oxazolidone-nitroimidazole coupling molecule, or stereoisomers, hydrates, deuterated compounds, esters, solvates, crystal forms, metabolites, pharmaceutically acceptable salts orthe prodrugs thereof can effectively resist anaerobic bacteria, and then treat anaerobic infections.

The externally applied lotion, named Tifu liquid, for treating aerobic bacteria and anaerobic bacteria infection consists of (in weight portions): Tinidazole 10-20 or Metronidazole 2-30, Furacin 1-2,sodium chloride 40-50 and water for injection 4000-6000. Compared with availble technology, the present invention is superior in that it contains Tinidazole capable of killing anaerobic bacteria, Furacin capable of killing aerobic bacteria and no glucose likely to form condition for bacteria to grow and propagate.

The invention discloses a compound tacrolimus cream and a preparation method and application thereof, the compound tacrolimus cream contains metronidazole, ketoconazole and tacrolimus, and the content of the tacrolimus is 0.03-0.1% (mass percent). The metronidazole, the ketoconazole and the tacrolimus have an excellent synergistic effect, can play a better role in inhibiting dermatophyte, saccharomycetes and some deep fungi, improve the treatment effect on anaerobic bacteria infection, have a targeted and radical treatment effect on inflammation caused by repeated attack of tinea cruris, tinea manuum, tinea pedis and the like, and the dosage is lower due to combination of the three components. The compound tacrolimus cream does not contain hormone components, so that the safety is higher, and the patient acceptability is better.